TG THERAPEUTICS, INC. (TGTX) earnings date
Mar 1, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 11 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | before open | 40 | 8-K |
| Q2 FY2026 | Mon, Aug 3, 2026 | before open | 34 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | before open | 34 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | before open | 35 | 8-K |
| Q1 FY2025 | Mon, May 5, 2025 | before open | 35 | 8-K |
| Q4 FY2024 | Mon, Mar 3, 2025 | before open | 62 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million Raises full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915–920 million, from $890–905 million Third-quarter 2026 total global revenue of approximately $260 million, including approximately $233 million in BRIUMVI U.S. net product revenue MSToronto2026 presentations highlight seven-year BRIUMVI efficacy and safety follow-up, positive ENHA" exhibit |
| Q3 FY2026 | "Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI." exhibit |
| Q3 FY2026 | "Weiss continued, “Looking ahead, we see a series of important catalysts over the next 18 to 24 months, including pivotal Phase 3 subcutaneous BRIUMVI results expected around year-end or early 2027, a potential launch of simplified IV initiation in mid-2027, additional clinical data from our expanding pipeline, and a potential subcutaneous BRIUMVI launch in 2028." exhibit |
| Q3 FY2026 | "Our increased full-year revenue guidance reflects the continued strength of our commercial business, while the approximately $100 million of shares repurchased during the quarter underscores our confidence in TG's long-term value.”" exhibit |
| Q3 FY2026 | "Top-line Phase 3 data are expected by year-end 2026 or early 2027." exhibit |
| Q2 FY2026 | "TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI ® Revenue Guidance" exhibit |
| Q2 FY2026 | "Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million" exhibit |
| Q2 FY2026 | "New York, NY, (August 3, 2026 ) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance." exhibit |
| Q2 FY2026 | "BRIUMVI delivered another outstanding commercial quarter, exceeding our expectations once again and putting us on track to exit 2026 at an approximately $1 billion annualized U.S. BRIUMVI revenue run rate." exhibit |
| Q2 FY2026 | "Top-line Phase 3 data is expected year-end 2026 or early 2027" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TGTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TGTX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TGTX/"><img src="https://veritasdata.dev/embed/TGTX.svg" alt="TGTX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TGTX/)
Script
<script async src="https://veritasdata.dev/embed/TGTX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TGTX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.